DGX Analyst Ratings
Quest Diagnostics Incorporated (DGX) operates in the Healthcare sector, specifically the Medical - Diagnostics & Research industry, with a market capitalization near $25.45B, listed on NYSE, employing roughly 51,500 people, carrying a beta of 0.54 to the broader market. Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Led by James E. Davis, public since 1996-12-17.
Analyst Ratings
In the October 2026 monthly count, 17 analysts rated DGX: 2 Strong Buy, 7 Buy, 7 Hold, 0 Sell and 1 Strong Sell.
Twelve months earlier, in October 2025: 19 analysts, 1 Strong Buy, 7 Buy, 10 Hold, 0 Sell and 1 Strong Sell.
Price Targets
- Average Target
- $250.00
- Median Target
- $255.00
- High
- $260.00
- Low
- $225.00
- Targets Published, Last 12 Months
- 27
Recent Price Targets
The 5 most recent of 27 price targets published in the last 12 months.
| Date | Firm | Analyst | Target | Price When Posted |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | Luke Sergott | $260.00 | $228.46 |
| Sep 21, 2026 | Truist Financial | Not named | $260.00 | $246.48 |
| Sep 8, 2026 | UBS | Not named | $245.00 | $235.58 |
| Jul 29, 2026 | Argus Research | Not named | $260.00 | $235.35 |
| Jul 24, 2026 | UBS | Kevin Caliendo | $232.00 | $231.30 |
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | maintain | Overweight | Overweight |
| Sep 21, 2026 | Truist Securities | maintain | Hold | Hold |
| Sep 8, 2026 | UBS | maintain | Neutral | Neutral |
| Jul 28, 2026 | JP Morgan | maintain | Neutral | Neutral |
| Jul 24, 2026 | UBS | maintain | Neutral | Neutral |
Quantitative Rating
DGX carries a model grade of B+ (overall score 3 of 5), computed from six valuation and financial measures (discounted cash flow, return on equity, return on assets, debt to equity, price to earnings and price to book), each scored 1 to 5. It is not an analyst rating.
How to Read DGX Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked DGX analyst ratings questions
- What is the DGX consensus price target?
- As of the latest aggregator update, Quest Diagnostics Incorporated (DGX) carries a consensus 12-month price target of $250.00. Target ranges run from a low of $225.00 to a high of $260.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on DGX?
- In the October 2026 monthly count, 17 analysts rated DGX, and the distribution tilts to the Buy side: 2 Strong Buy, 7 Buy, 7 Hold, 0 Sell and 1 Strong Sell. Rating consensus moves slowly relative to price; it reflects sell-side conviction over a 12-month horizon rather than near-term momentum.
- What recent ratings actions has DGX seen?
- The five most recent ratings actions on DGX appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect DGX options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.